ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Role of epigallocatechin-3- gallate in the regulation of known and novel microRNAs in breast carcinoma cells.Frontiers in genetics · 2022Article
- Article
- Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.Bioscience reports · 2020Article
- AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.Molecular cancer · 2019Review
- MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulatingCancer management and research · 2019Article
- A Genetic Variant of miR-34a Contributes to Susceptibility of Ischemic Stroke Among Chinese Population.Frontiers in physiology · 2019Article
- Characterization of the miRNA regulators of the human ovulatory cascade.Scientific reports · 2018Article
- Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.BMC cancer · 2018Article
- Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2018Article
- Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.Molecular therapy. Nucleic acids · 2017Article
- MicroRNAs in gynecological cancers: Small molecules with big implications.Cancer letters · 2017Review
- Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis.Physiological reports · 2017Article
- Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.World journal of gastroenterology · 2017Article
- Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.Oncotarget · 2017Review
- NEAT1 regulates cell proliferation and apoptosis of ovarian cancer by miR-34a-5p/BCL2.OncoTargets and therapy · 2017Article
- The Receptor Tyrosine Kinase AXL in Cancer Progression.Cancers · 2016Review
- MicroRNA Exert Macro Effects on Cancer Bone Metastasis.Current osteoporosis reports · 2016Review
- Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.BMC cancer · 2016Article
- MicroRNA‑205 promotes the tumorigenesis of nasopharyngeal carcinoma through targeting tumor protein p53-inducible nuclear protein 1.Molecular medicine reports · 2015Article
- MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
- Retraction · 2017-04-20Compromised Peer Review · Investigation by Journal/Publisher · · Journal published by SAGE starting in 2017
- Retracted
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence has suggested that dysregulation of microRNAs (miRNAs) could contribute to tumor progression. The miR-34 family is directly transactivated by tumor suppressor p53 which is frequently mutated in various cancers; however, the effect of miR-34a on the ovarian cancer cells remains unclear. The aim of the paper was to study the expression of miR-34a in ovarian cancer and miR-34a's relation to the cell proliferation and metastasis in ovarian cancer in vitro. miR-34a expression was determined by quantitative RT-PCR in a panel of 60 human ovarian cancer samples. Functional characterization of miR-34a was accomplished by reconstitution of miR-34a expression in ovarian cancer cells by determining changes in proliferation, migration, and invasion. Our results showed that miR-34a is downregulated in ovarian cancer tissues compared with the corresponding adjacent non-neoplastic tissues, and the expression level of miR-34a was significantly lower in ovarian cancer cell lines in comparison with normal human fallopian tube epithelial cell line. The 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-diphenytetrazoliumromide (MTT) assay revealed significant cell proliferation inhibition in miR-34a transfectant compared with the control from HO8910 and SKOV3 cells, which displayed lowest expressions of miR-34a. Furthermore, the transwell assay also showed significant cell migration inhibition in miR-34a transfectant, compared with cell lines transfected with NC. Overexpression of miR-34a led to the inhibition of AXL expression, indicating that AXL is a target gene for miR-34a. Our data suggest that miR-34a may function as a tumor suppressor through repression of oncogenic AXL in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.